COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference
09/09/2024
PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
09/09/2024
Company plans to launch multiple direct-from-blood diagnostics over the next 15 months for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris LEXINGTON, Mass., Sept. 09, 2024 (GLOBE [...]
Stereotaxis to Present at Upcoming Investor Conferences
09/09/2024
ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and [...]
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
09/09/2024
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and [...]
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
09/09/2024
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on [...]
Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
09/09/2024
Collaboration Aims to Expedite the Development of Critical Solutions for Public Health Threats, Including Pandemic Preparedness and Emerging Infectious Diseases DURHAM, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scorpius [...]
Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO
09/09/2024
Purchases Signal Leadership Confidence and Commitment to Company ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on [...]
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
09/09/2024
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage [...]
September 2024 Letter to Shareholders
09/09/2024
VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or the “Company”). A year in which we have made significant strides as a [...]
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
09/09/2024
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]
Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year
09/09/2024
- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively - NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ( [...]
Cassava Sciences Names Rick Barry as Chief Executive Officer
09/09/2024
Claude Nicaise, M.D. appointed Chairman of the Board AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it [...]
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
09/09/2024
WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
09/09/2024
TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara [...]
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
09/09/2024
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor [...]
Creyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of Directors
09/09/2024
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Creyon Bio , Inc. ("Creyon"), a clinical-stage leader in AI/machine learning-enabled engineering of oligonucleotide-based medicines (OBMs), [...]
SAFE - Nouvel engagement de financement d’un montant minimum net de 3 M€ dans la perspective de la validation du plan de continuation
08/09/2024
Avertissement : La société SAFE SA (la « Société ») a mis en place un financement sous forme d’obligations convertibles en actions nouvelles ou existantes (OCEANE) avec Global Corporate Finance Opportunities 20 (« GCFO [...]
RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
08/09/2024
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy 1 Results from an interim analysis featured in late [...]
Avalyn Presents Multiple Posters on AP01 for Pulmonary Fibrosis, Including MIST Phase 2b Trial Design and ATLAS Phase 1b Study Post-hoc Analyses, at ERS 2024
08/09/2024
Trial Design Showcased for the MIST Study, a Recently Initiated Phase 2b Clinical Trial, Evaluating the Efficacy and Safety of AP01 (inhaled pirfenidone) Compared to Placebo in Patients with Progressive Pulmonary [...]

Pages